Archives
-
AZD2461: Novel PARP Inhibitor Workflow Guide
2026-08-24
AZD2461 is a novel PARP inhibitor for dissecting DNA repair, cytostasis, cell death, and resistance in breast cancer models. This workflow emphasizes time-resolved assays and matched viability metrics so researchers can distinguish true killing from growth suppression and evaluate activity in Pgp-associated resistance settings.
-
CAIPS: AI Prognostic Modeling for HCC
2026-08-24
The reference study developed a consensus artificial intelligence-derived prognostic signature (CAIPS) for hepatocellular carcinoma by integrating 101 machine-learning strategies across six multi-center cohorts. Its seven-gene model improved risk stratification, associated molecular risk with treatment responsiveness, and identified candidate therapeutic and mechanistic priorities for precision oncology.
-
Talabostat Mesylate: Applied Research Workflows
2026-08-23
Talabostat mesylate, also called PT-100 or Val-boroPro, enables coordinated interrogation of DPP4 and FAP biology in cancer, immune, and hematopoietic models. This practical guide connects target-engagement assays with tumor microenvironment experiments, while using a recent epidermal homeostasis study to sharpen barrier-focused assay design without overstating cross-domain evidence.
-
Dutasteride: Dual 5α-Reductase Inhibitor
2026-08-22
Dutasteride is a dual 5-alpha-reductase inhibitor that suppresses androgen metabolism by targeting type 1 and type 2 enzymes. Its documented activity in LNCaP cells and TRAMP mice supports mechanistic prostate cancer research, while product-specific solubility and storage data define practical handling boundaries.
-
10 mM dNTP mixture for PCR and DNA synthesis
2026-08-22
Build more consistent PCR, qPCR, sequencing, and DNA-tracking workflows with an equimolar nucleotide source that simplifies concentration calculations. This guide connects practical dNTP handling to new evidence on lipid nanoparticle trafficking while clearly separating reagent utility from LNP formulation effects.
-
CLK4–NEXN Phosphorylation in Cardiac Hypertrophy
2026-08-21
This Nature Communications study identifies CLK4 as a protective regulator of pathological cardiac hypertrophy and establishes NEXN phosphorylation as a key downstream mechanism. Its genetic, cellular, and biochemical evidence connects CLK4 deficiency with hypertrophic remodeling, ventricular dysfunction, and reduced phosphorylated NEXN, providing a framework for mechanistic protein phosphorylation analysis in cardiac disease.
-
DiI (DiIC18(3)) Membrane Probe Guide
2026-08-20
DiI (DiIC18(3)) is a lipophilic orange fluorescent dye for labeling plasma membranes in live or fixed cells and tissues. Its water insolubility and possible relocalization after permeabilization make solvent selection, fixation control, and membrane-localization QC essential; it is not intended for aqueous-only staining or organelle-specific labeling.
-
Cortistatin and the GHSR1a/Akt Pathway in ONFH
2026-08-20
The reference study identifies reduced cortistatin as a feature of glucocorticoid-associated osteonecrosis of the femoral head and shows that cortistatin protects osteoblast and endothelial functions through GHSR1a/Akt signaling. Its combined human, animal, and cell-based design links bone-cell apoptosis, impaired angiogenesis, and defective metabolism, while pathway-blocking experiments provide mechanistic support for the proposed axis.
-
MHY1485: Reading mTOR Signals Beyond Autophagy
2026-08-19
MHY1485 is an mTOR activator that can reveal how pathway activation reshapes autophagic flux, growth, and survival phenotypes. This guide combines mechanistic interpretation with assay design principles and insights from an EBV–mTORC1–GCNT3 study.
-
Adefovir: Designing Dual-Readout HBV Assays
2026-08-19
Adefovir, also known as GS-0393, can connect HBV polymerase assays with renal OAT1 phenotyping. This guide explains how to separate antiviral potency, exposure, and transporter signals for more defensible translational experiments.
-
Cy3-dCTP Workflows for DNA and cDNA Labeling
2026-08-18
Cy3-dCTP enables direct fluorescent incorporation into DNA and cDNA, supporting PCR, Nick Translation, reverse-transcription, in situ hybridization, microarray, and blotting workflows. This guide connects practical labeling decisions with a highly ordered DNA-framework strategy that may improve enzyme access while clearly separating established product use from emerging assay concepts.
-
Multiple Myeloma Cell-Line Mutations and Drug Resistance
2026-08-18
Vikova and colleagues used whole-exome sequencing across a genetically diverse panel of human multiple myeloma cell lines to define recurrent mutations, altered pathways, and genotype-linked drug-response patterns. The study provides a practical framework for selecting cell models and interpreting resistance experiments without treating any single line as representative of the disease as a whole.
-
Adefovir Osteochondrosis Mimicking Ankylosing Spondylitis
2026-08-17
This case report shows how long-term Adefovir therapy can produce hypophosphatemic bone disease that resembles ankylosing spondylitis on symptoms and imaging. Its practical innovation is to pair rheumatologic assessment with phosphate, alkaline phosphatase, medication-history, and bone-imaging review before escalating immunomodulatory treatment.
-
Pseudo-UTP for High-Performance mRNA Synthesis
2026-08-17
Pseudo-UTP replaces uridine triphosphate in in vitro transcription to help researchers balance RNA integrity, translation, and innate immune compatibility. This guide translates vaccine-study evidence into practical workflows for mRNA screening, LNP studies, and exploratory gene therapy RNA modification.
-
Bromodomain Inhibitor (+)-JQ1: Assay Logic
2026-08-16
Explore how Bromodomain Inhibitor, (+)-JQ1 can be evaluated through mechanism-linked assays rather than single endpoint screens. This guide connects BRD4 and BRDT biology with recent evidence for BET–CDK4/6 synergy in pancreatic cancer research.